Xavier T. Reveles - Sep 18, 2023 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Chief Operating Officer
Signature
/s/ Xavier Trinidad Reveles
Stock symbol
BIAF
Transactions as of
Sep 18, 2023
Transactions value $
$0
Form type
3
Date filed
9/25/2023, 05:12 PM
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIAF Common Stock 3.62K Sep 18, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIAF Stock Option (Right to Buy) Sep 18, 2023 Common Stock 2.86K $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) Sep 18, 2023 Common stock 1.43K $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) Sep 18, 2023 Common Stock 1.43K $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) Sep 18, 2023 Common Stock 2.14K $7.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock award was granted on November 17, 2022 and vest pro rata monthly over one year.
F2 This stock option is fully vested and reflects a stock split that occurred on June 23, 2022.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Xavier Reveles)